vs
Side-by-side financial comparison of Bank First Corp (BFC) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Bank First Corp is the larger business by last-quarter revenue ($44.9M vs $27.5M, roughly 1.6× Sanara MedTech Inc.). Bank First Corp runs the higher net margin — 45.8% vs -5.9%, a 51.6% gap on every dollar of revenue. On growth, Bank First Corp posted the faster year-over-year revenue change (12.1% vs 4.6%). Bank First Corp produced more free cash flow last quarter ($51.0M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 9.1%).
First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
BFC vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $27.5M |
| Net Profit | $18.4M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 51.0% | 23.5% |
| Net Margin | 45.8% | -5.9% |
| Revenue YoY | 12.1% | 4.6% |
| Net Profit YoY | 4.8% | 5.3% |
| EPS (diluted) | $1.87 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $27.5M | ||
| Q3 25 | $44.2M | $26.3M | ||
| Q2 25 | $41.6M | $25.8M | ||
| Q1 25 | $43.1M | $23.4M | ||
| Q4 24 | $40.1M | $26.3M | ||
| Q3 24 | $40.8M | $21.7M | ||
| Q2 24 | $38.9M | $20.2M | ||
| Q1 24 | $37.7M | $18.5M |
| Q4 25 | $18.4M | $-1.6M | ||
| Q3 25 | $18.0M | $-30.4M | ||
| Q2 25 | $16.9M | $-2.0M | ||
| Q1 25 | $18.2M | $-3.5M | ||
| Q4 24 | $17.5M | $-1.7M | ||
| Q3 24 | $16.6M | $-2.9M | ||
| Q2 24 | $16.1M | $-3.5M | ||
| Q1 24 | $15.4M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 51.0% | 23.5% | ||
| Q3 25 | 50.8% | 11.2% | ||
| Q2 25 | 49.7% | -0.1% | ||
| Q1 25 | 51.3% | -8.9% | ||
| Q4 24 | 54.4% | 18.6% | ||
| Q3 24 | 50.7% | 3.6% | ||
| Q2 24 | 51.0% | -14.3% | ||
| Q1 24 | 45.6% | -8.3% |
| Q4 25 | 45.8% | -5.9% | ||
| Q3 25 | 40.7% | -115.5% | ||
| Q2 25 | 40.5% | -7.8% | ||
| Q1 25 | 42.3% | -15.1% | ||
| Q4 24 | 49.3% | -6.5% | ||
| Q3 24 | 40.6% | -13.2% | ||
| Q2 24 | 41.3% | -17.4% | ||
| Q1 24 | 40.8% | -9.5% |
| Q4 25 | $1.87 | $-0.32 | ||
| Q3 25 | $1.83 | $-3.40 | ||
| Q2 25 | $1.71 | $-0.23 | ||
| Q1 25 | $1.82 | $-0.41 | ||
| Q4 24 | $1.75 | $-0.18 | ||
| Q3 24 | $1.65 | $-0.34 | ||
| Q2 24 | $1.59 | $-0.41 | ||
| Q1 24 | $1.51 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $243.2M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $643.8M | $5.9M |
| Total Assets | $4.5B | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $243.2M | $16.6M | ||
| Q3 25 | $126.2M | $14.9M | ||
| Q2 25 | $120.3M | $17.0M | ||
| Q1 25 | $300.9M | $20.7M | ||
| Q4 24 | $261.3M | $15.9M | ||
| Q3 24 | $204.4M | $16.3M | ||
| Q2 24 | $99.0M | $6.2M | ||
| Q1 24 | $83.4M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $643.8M | $5.9M | ||
| Q3 25 | $628.1M | $6.1M | ||
| Q2 25 | $612.3M | $35.4M | ||
| Q1 25 | $648.4M | $36.7M | ||
| Q4 24 | $639.7M | $39.4M | ||
| Q3 24 | $628.9M | $39.8M | ||
| Q2 24 | $614.6M | $41.7M | ||
| Q1 24 | $609.3M | $43.3M |
| Q4 25 | $4.5B | $72.9M | ||
| Q3 25 | $4.4B | $71.1M | ||
| Q2 25 | $4.4B | $98.8M | ||
| Q1 25 | $4.5B | $96.4M | ||
| Q4 24 | $4.5B | $88.1M | ||
| Q3 24 | $4.3B | $88.5M | ||
| Q2 24 | $4.1B | $73.4M | ||
| Q1 24 | $4.1B | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.5M | $3.9M |
| Free Cash FlowOCF − Capex | $51.0M | $3.9M |
| FCF MarginFCF / Revenue | 113.6% | 14.0% |
| Capex IntensityCapex / Revenue | 25.5% | 0.3% |
| Cash ConversionOCF / Net Profit | 3.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $75.8M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.5M | $3.9M | ||
| Q3 25 | $15.5M | $2.2M | ||
| Q2 25 | $11.9M | $2.7M | ||
| Q1 25 | $6.2M | $-2.0M | ||
| Q4 24 | $65.8M | $932.0K | ||
| Q3 24 | $18.8M | $2.1M | ||
| Q2 24 | $14.9M | $-1.4M | ||
| Q1 24 | $1.3M | $-1.6M |
| Q4 25 | $51.0M | $3.9M | ||
| Q3 25 | $12.5M | $1.1M | ||
| Q2 25 | $8.2M | $902.7K | ||
| Q1 25 | $4.0M | $-3.7M | ||
| Q4 24 | $58.6M | $859.9K | ||
| Q3 24 | $16.9M | $2.0M | ||
| Q2 24 | $13.7M | $-1.5M | ||
| Q1 24 | $551.0K | $-1.7M |
| Q4 25 | 113.6% | 14.0% | ||
| Q3 25 | 28.2% | 4.2% | ||
| Q2 25 | 19.8% | 3.5% | ||
| Q1 25 | 9.3% | -15.9% | ||
| Q4 24 | 146.3% | 3.3% | ||
| Q3 24 | 41.5% | 9.4% | ||
| Q2 24 | 35.3% | -7.3% | ||
| Q1 24 | 1.5% | -9.0% |
| Q4 25 | 25.5% | 0.3% | ||
| Q3 25 | 6.7% | 4.0% | ||
| Q2 25 | 8.7% | 6.8% | ||
| Q1 25 | 5.0% | 7.4% | ||
| Q4 24 | 18.0% | 0.3% | ||
| Q3 24 | 4.5% | 0.0% | ||
| Q2 24 | 3.1% | 0.3% | ||
| Q1 24 | 2.1% | 0.4% |
| Q4 25 | 3.40× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 3.75× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 0.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFC
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
